GPNMB and atherosclerosis: One such protein termed a ‘seno-antigen’, glycoprotein nonmetastatic melanoma protein B (GPNMB), was formulated into a senolytic vaccine and injected into progeroid mice, effectively reducing SC burden, alleviating pathological effects of obesity and atherosclerosis, and extending lifespan (Suda et al., 2021).